Data monitoring in randomized controlled trials: Surveys of recent practice and policies

Clinical Trials

Volumn 2, Issue 1, 2005, Pages 22-33

  Clemens, Felicity ^a   Elbourne, Diana ^a   Derbyshire, Janet ^b   Pocock, Stuart ^a   Grant, A M ^c   Altman, D G ^c   Babiker, A B ^c   Campbell, M K ^c   McLeer, S K ^c   Parmar, M K B ^c   Spiegelhalter, D J ^c   Sydes, M R ^c   Walker, A E ^c   Wallace, S A ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Med Res Cncl Clinical Trials Unit   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEALTH CARE POLICY; HEALTH SERVICE; HEALTH SURVEY; HUMAN; INFORMATION PROCESSING; INTERNATIONAL COOPERATION; MEDICAL RESEARCH; ORGANIZATION; PRIORITY JOURNAL; PROFESSIONAL STANDARD; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STRUCTURE ANALYSIS; UNITED KINGDOM;

CLINICAL TRIALS DATA MONITORING COMMITTEES; DATA INTERPRETATION, STATISTICAL; DECISION MAKING, ORGANIZATIONAL; GREAT BRITAIN; HUMANS; ORGANIZATIONAL POLICY; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 20044385050     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1191/1740774505cn064oa     Document Type: Review

References (21)

1. Ellenberg S, Fleming T, DeMets D. Data monitoring committees in clinical trials: a practical perspective. Chichester: John Wiley and Sons Ltd, 2002.
2. Hawkins BS. Data monitoring committees for multicenter clinical trials sponsored by the National Institutes of Health. I. Roles and membership of data monitoring committees for trials sponsored by the National Eye Institute. Controlled Clinical Trials 1991; 12: 424-37.
3. Geller NL, Stylianou M. Practical issues in data monitoring of clinical trials: summary of responses to a questionnaire at NIH. Statistics in Medicine 1993; 12: 543-51.
4. George SL. A survey of monitoring practices in cancer clinical trials. Statistics in Medicine 1993; 12: 435-50.
5. Grant AM, Sydes M, McLeer S et al. Issues in data monitoring and interim analysis of trials (the DAMOCLES study). Health Technology Assessment, in press.
6. Sydes MR, Spiegelhalter DJ, Altman DG, Babiker AB, Parmer MKB and the DAMOCLES group. Systematic review of Data Monitoring Committees in Randomised Controlled Trials. Clinical Trials 2004; 1: 60-79.
7. Walker AE, McLeer SK and the DAMOCLES group. Small group processes relevant to Data Monitoring Committees: an overview of reviews. Clinical Trials 2004; 1: 282-96.
8. Sydes MR, Altman DG, Babiker AB, Parmar MKB, Spiegelhalter DJ and the DAMOCLES group. Reported Use of Data Monitoring Committees in the Main Published Reports of Randomised Controlled Trials: A Cross-sectional Study. Clinical Trials 2004; 1: 48-59.
9. Medical Research Council. MRC guidelines for good clinical practice in clinical trials. London: MRC, 1998.
10. Kiri A, Tonascia S, Meinert CL. The relationship between treatment effects monitoring in clinical trials and early stops. Clinical Trials 2004; 1: 40-47.
11. Ellenberg SS, George SL. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership? Statistics in Medicine 2004, 23: 1503-05.
12. DeMets DL, Fleming TR. The independent statistician for data monitoring committees. Statistics in Medicine 2004; 23: 1513-17.
13. Lachin JM. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials. Statistics in Medicine 2004; 23: 1519-21.
14. Siegel JP, O'Neill RT, Temple R, Campbell G, Foulkes MA. Independence of the statistician who analyses unblinded data. Statistics in Medicine 2004; 23: 1527-29.
15. Pocock SJ. A major trial needs three statisticians: why, how and who? Statistics in Medicine 2004; 23: 1535-39.
16. Meinert CL. Masked monitoring in clinical trials - blind stupidly? New Engl J Med 1998; 338: 1381-82.
17. US Food and Drug Administration. Guidance for clinical trial sponsors on the establishment and operation of clinical trial data monitoring committees. Rockville, MD: FDA, November 2001. http://www.fda.gov/cber/gdlns/clindatmon.htm Accessed 15 September 2004.
18. Meinert CL. Clinical trials and treatment effects monitoring. Control Clin Trials 1998; 19: 515-22.
19. O'Neil RT. Conclusions. Statist Med 1994; 13: 1493-99.
20. Siebert C, Clark CM Jr. Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Control Clin Trials 1993; 14: 30-44.
21. Grant AM, Altman DG, Babiker AB et al. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet, in press.